Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
Phase:
Phase 2
Details
Lead Sponsor:
Anaconda Pharma
Vaxart